Tyme
Jonathan Eckard is the current Chief Business Officer at Tyme. Jonathan has previously served as the Chief Business & Strategy Officer at Sellas Life Sciences, Biotechnology Analyst at Barclays, and Small/Mid-Cap Biotechnology Analyst at Citi. Jonathan has also worked as a Biotechnology Equity Research at Leerink Swann and HSBC Securities. Jonathan Eckard began their career as a Graduate Research Assistant at NYU School of Medicine in 1997 and has since amassed over 20 years of experience in the biotechnology field.
Jonathan Eckard's educational career began with a Bachelor of Science in Biochemistry from Ohio University. Jonathan then pursued a Master of Science in Toxicology from New York Medicine Jobs. Finally, they obtained their Ph.D. in Toxicology/Carcinogenesis from New York Medicine Jobs.
Some of their coworkers include Frank L. Porfido - CFO, Thomas Cook - VP, Public Relations, and Steven Hoffman - Chief Science Officer. Their manager is Richie Cunninggam, CEO.
This person is not in any offices
Tyme
Tyme Technologies, Inc. is a research and development company focused on creating medicines that utilizes the body’s immune system to treat diseases. We at Tyme believe that the body has the ability to fight off major diseases and heal itself.